Evaluation of Allergic Reactions Following Intravenous Infusion of PolyvalentAntivenom in Snakebite Patients / Ghafar-Ali Mahmoudi, Maryam Ahadi, Ali Fouladvand, Bareza Rezaei, Zahra Bodagh, Peyman Astaraki

Background: Antivenom is a gold-standard treatment for snakebite envenoming. However,adverse reactions to snake antivenom are common in many parts. Objective: The aim of this study was to evaluate the allergic reactions following intravenous administrationof antivenom sera. Methods: This was retrospective study conducted on snakebites patients referred to the RahimiHospital in Khorramabad. The files of these patients were accessed for demographic data,snakebite-related data, treatment provided, clinical presentation and allergic reaction status as a resultof antivenom treatment. Results: 141 cases were investigated, including 73.8% male and 26.2% female patients. The meanage of the patients was 38.1±17.1 years. Age group 30-39 years accounted for the highest numberof snakebite cases (24.1%). A majority of victims (89.4%) were from rural areas. Most of the patients(51.8%) were bitten in the spring and highest number of snakebite were reported in May(39.1%). The most common site of snakebite was lower extremities (50.4%) and upper extremities(44.7%). Among clinical feature of snakebite, pain was the most prevalent in 135 cases (95.7%) followedby swelling (83.7%). The mean antivenom vials used were 6.5±3.7 vials. Allergic reactionsoccurred in 6 patients (4.26%); reactions were mild in 5 patients and severe in 1 patient. The commonestpresentation was maculopapular rash (1.4%) and the least common were headache(0.71%), nausea (0.71%), fever (0.71) and hypotension (0.71%). Conclusion: Snakebite is one of the significant life-threatening environmental events. Immediateantivenom treatment can reduce mortality however, patients should be carefully monitored for adverseallergic reactions.

Medienart:	E-Artikel

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	Zur Gesamtaufnahme - volume:20
Enthalten in:	Anti-inflammatory & anti-allergy agents in medicinal chemistry - 20(2021), 4, Seite 6

Sprache:	Englisch

Beteiligte Personen:	Mahmoudi, Ghafar-Ali [VerfasserIn] Ahadi, Maryam [VerfasserIn] Fouladvand, Ali [VerfasserIn] Rezaei, Bareza [VerfasserIn] Bodagh, Zahra [VerfasserIn] Astaraki, Peyman [VerfasserIn]

Links:	FID Access [lizenzpflichtig]

Umfang:	1 Online-Ressource (6 p)

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	KFL011145226